Form 4: CareDx Director Peter Maag Sells 10,000 Shares Under Pre-Arranged Trading Plan

CareDx, Inc. Director Peter Maag sold 10,000 shares of common stock on June 17, 2025, at a weighted average price of $19.242 per share, pursuant to a Rule 10b5-1 trading plan.

Summary

• Peter Maag, a Director of CareDx, Inc. (CDNA), sold 10,000 shares of the company's common stock.
• The transaction occurred on June 17, 2025.
• The shares were sold at a weighted average price of $19.242, with individual sales ranging from $18.80 to $19.52.
• Following this transaction, Mr. Maag beneficially owns 318,846 shares of CareDx common stock.
• The sale was executed under a Rule 10b5-1 trading plan, which Mr. Maag adopted on August 21, 2024.

Sentiment

Score: 5

Explanation: The sale of shares by a director could be seen as slightly negative, but the fact that it was conducted under a pre-arranged Rule 10b5-1 plan significantly mitigates any negative sentiment, making it largely neutral as it indicates a planned financial move rather than a reaction to new company-specific information.

Positives

• The sale was conducted under a pre-arranged Rule 10b5-1 trading plan, indicating it was not based on immediate, non-public information and was planned well in advance.

Negatives

• A director selling shares can sometimes be perceived negatively by the market, as it reduces their direct stake in the company.

Risks

• While the sale was pre-planned, significant insider selling, even under 10b5-1 plans, can sometimes be interpreted by investors as a lack of confidence, potentially impacting stock price.

Future Outlook

NA

Industry Context

This Form 4 filing is a routine disclosure of an insider stock transaction and does not provide specific insights into broader industry trends or competitive landscape for the diagnostics or healthcare sectors. Such filings are standard for publicly traded companies and reflect individual executive financial planning rather than corporate strategy.

Stakeholder Impact

• Shareholders: The sale by a director, even if pre-planned, might lead to minor concerns about insider confidence, but the impact is generally limited given the 10b5-1 plan. The reduction in direct ownership by a director is a factual change for shareholders.

Key Dates

Keywords

CareDx, CDNA, Peter Maag, Insider Trading, Form 4, SEC Filing, Stock Sale, Director, Rule 10b5-1, Common Stock